The immuno-oncology therapy developer has amassed at least $190m of overall funding since emerging out of Stanford University.
Synthekine, a US-based immuno-oncology therapy spinout of Stanford University, has raised $108m in a series B round co-led by Deerfield Management and Janus Henderson Investors.
Lilly Asia Ventures, a corporate venturing vehicle for pharmaceutical firm Eli Lilly. RA Capital Management, Rock Springs Capital, Omega Funds, Samsara BioCapital, Canaan Partners, Emerson Collective, Column Group and its affiliate TCG Crossover, as well as an undisclosed healthcare investor also took part.
Founded in 2018, Synthekine is studying engineered cytokine – molecules…
